RxDoctor Payments Data

Roi Altit, MD

Interventional Cardiology · Langhorne, PANPI 1376777169

Payments from drug & device makers

$22,571in general payments, 2019–2025

Across 473 payments — averaging $47.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Edwards Lifesciences$3K
  • Abbott$3K
  • Abiomed$2K
  • Penumbra, Inc.$2K
  • Boston Scientific$1K
  • plus $5K from 34 others
$2,000in research payments, 2019–2025

Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$2K

What the payments were for

  • Travel & lodging$8,30337%
  • Food & beverage$14,08962%
  • Education$1791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,571 in reported general payments places this provider in the 65th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$92,539
Medicare patients
508
Services billed
974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$54,944
XareltoRivaroxaban31$31,057
FarxigaDapagliflozin Propanediol36$28,277
EntrestoSacubitril/Valsartan25$25,772
JardianceEmpagliflozin13$11,397
Ezetimibe39$2,211
Atorvastatin Calcium154$1,554
Valsartan34$1,189
Diltiazem 24hr Er (Cd)Diltiazem Hcl29$983
Flecainide Acetate20$885
Amlodipine Besylate116$839
Metoprolol Succinate63$791
Rosuvastatin Calcium55$634
ClopidogrelClopidogrel Bisulfate54$579
Carvedilol74$438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$252$54,94451 claims
Johnson & JohnsonXarelto$393$31,05731 claims
AstraZenecaFarxiga$745$28,27736 claims
NovartisEntresto$278$25,77225 claims
Boehringer IngelheimJardiance$67$11,39713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →